Skip to content

News

Asgard Therapeutics awarded with Sweden’s SWElife Innovation Grant

Asgard Therapeutics was awarded with Sweden’s SWElife innovation grant. Swelife is a strategic innovation programe, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programe’s partners. Swelife supports collaboration within academia,
Read More

Fábio Rosa highlighted as one of the young 34 promising Scanian personalities of 2020

Rapidus and PwC ​​highlighted Fábio Rosa as one of 34 young promising Scanian personalities and driven entrepreneurs of this year.
Read More

Asgard Therapeutics highlighted at the Medicon Valley Alliance/ Øresundsinstituttet report

In a new survey published by Øresund Institute and Medicon Valley Alliance, Asgard Therapeutics was highlighted as one of 426 life science companies in Skåne.  https://www.oresundsinstituttet.org/life-science-skane/?utm_campaign=unspecified&utm_content=unspecified&utm_medium=email&utm_source=apsis-anp-3
Read More

Filipe Pereira awarded with Mats Paulsson Grant 2020

Mats Paulsson Foundations awarded Filipe Pereira, co-founder of Asgard Therapeutics, with a Mats Paulsson Grant 2020. Since 2019, the foundation has focused on grants for academic research projects that in
Read More

Filipe Pereira awarded with the KiiLN Postdoctoral Entrepreneurship Award

The KiiLN- Keystone for Incubating Innovation in Life Sciences Network team and Icahn School of Medicine at Mount Sinai awarded Filipe Pereira, co-founder of Asgard Therapeutics, the KiiLN Postdoctoral Entrepreneurship Award. This award
Read More

Asgard Therapeutics becomes a SmiLe member

Asgard Therapeutics AB has been admitted to SmiLe Incubator as the next step to move forward on the pre-clinical studies of their lead program TrojanDC. https://news.smileincubator.com/posts/pressreleases/immunotherapy-company-asgard-therapeutics-is
Read More

Asgard featured on the Pharma Industry report about ATMPs in Sweden

Advanced Therapies Medical Products (ATMPs) are considered the “drugs of the future”. These are based on gene, cell and tissue products. Sweden has the ambitious goal of becoming a leader
Read More

Filipe Pereira, Cristiana Pires and Fábio Rosa, co-founders of Asgard Therapeutics, awarded with the Lund University and Sparbanken Skåne’s prize for future innovations

Together with Sparbanken Skåne, in collaboration with the Sparbanksstiftelsen Finn, Lund University awarded Filipe Pereira, Cristiana Pires and Fábio Rosa the Lund University and Sparbanken Skåne’s prize for future innovations.
Read More

Filipe Pereira, co-founder of Asgard Therapeutics, awarded with a BII PreSeed grant

The BioInnovation Institute (BII) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with DKK 3.5M to advance pre-clinical development of dendritic cell reprogramming and define its regulatory roadmap towards the clinic.
Read More

Asgard Therapeutics awarded Vinnova’s Innovative Startup Step 2

Swedish start-up company Asgard Therapeutics has been awarded the second step of Vinnova’s Innovative Startup program in order to further develop a new cancer immunotherapy based on dendritic cell reprogramming.
Read More

Asgard Therapeutics awarded with Lund University Innovation VFT+ Funds

Asgard was selected to receive Vinnova’s VFT+ funds managed by LU Innovation for verification activities of TrojanDC towards partners, customers and investors. 
Read More

Fábio Rosa, co-founder of Asgard Therapeutics, selected for Forbes 30 under 30 List – Europe – Science & Healthcare 2020

Fábio Rosa, co-founder of Asgard Therapeutics, was selected by Forbes among 30 brightest young entrepreneurs, innovators and game changers in Science and Healthcare segment. https://www.forbes.com/profile/fabio-rosa/#7376307670f8
Read More